Prostate cancer is the most commonly diagnosed cancer in men in the United States, with approximately 233,000 new cases diagnosed each year. Advancements in medical treatments and screening strategies have resulted in significant improvements in patient survival. The 5-year survival rate for prostate cancer has increased more than 31 percent in the past 25 years, and it is estimated that there are currently 2.8 million prostate cancer survivors in the U.S. However, there are limited clinical guidelines to address the long-term and late effects of cancer treatment in survivors.
Brian M. Rivers, Ph.D., M.P.H., assistant member of the Health Outcomes & Behavior Program at Moffitt Cancer Center, was part of a 16-member expert workgroup created by the American Cancer Society to analyze published studies and existing guidelines to develop a new set of clinical guidelines for long-term patient care after prostate cancer treatment.
